Updated: Merck commits up to $610M to buy out preclinical biotech and its neurodegenerative disease work
Merck is snapping up a private biotech focused on genetically defined neurodegenerative disorders and rare diseases, promising to pay $610 million if everything works out.
Caraway Therapeutics, based in Cambridge, MA, is developing a slate of preclinical small molecule therapeutics “that boost cellular clearance pathways to restore balance” — with a focus on purging toxic proteins from cells, such as tau and alpha-synuclein.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.